Top Markets
Coin of the day
GH Research PLC GH Research PLC

GH Research PLC

GHRS
Classement en actions #6594
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to... GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
Prix de l'action
$28.53
Capitalisation boursière
$1.96B
Changement (1 jour)
-1.65%
Changement (1 an)
109.32%
Pays
IE
Échange GH Research PLC (GHRS)

Catégorie

Historique du prix de l'action pour GH Research PLC (GHRS)
Prix de clôture le plus élevé : $29.28 le 2026-08-01

Prix de clôture le plus bas : $20.43 le 2021-06-01
Historique du prix de l'action de GH Research PLC de 2021 à 2026
Performance annuelle du prix de l'action
Année Performance
2026 (TTM) 34.51%
2025 71.80%
2024 35.29%
2023 -44.18%
2022 -56.09%
2021 0.00%
Prix de l'action pour des entreprises similaires ou concurrentes
Entreprise Prix de l'action Variation 1a% Pays
$548.36 40.94%
US
$1.06K 49.46%
NL
$122.63 -12.65%
AU
$140.81 461.00%
US
$765.25 7.19%
CH